Clinical trial · Interventional
Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan
A Phase I Open-label, Multi-center, Dose-escalation and Safety Expansion Study to Assess Safety, Tolerability, and Pharmacokinectics of AZD7762 Administered as a Single Intravenous Agent and in Combination With Weekly Standard Dose of Irinotecan in Patients With Advanced Solid Malignancies.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Termination of the study was made after a full review of program data and assessment of the current risk-benefit profile.
Summary
Brief summary (as posted)
This is an open-label, multi-center, dose-escalation and safety expansion, Phase I study to evaluate the safety, tolerability, and pharmacokinectics and to investigate biomarker changes of AZD7762 administered as a single intravenous unit and in combination with irinotecan. The study is sponsored by AstraZeneca.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid Malignancies | — | UNRESOLVED | — |
| Advanced Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AZD7762 | Drug | Checkpoint Kinase Inhibitor AZD7762 | ALIAS |
| Irinotecan | Drug | Irinotecan | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- description
- AZD7762 monotherapy followed by AZD7762 + irinotecan
- interventionNames
- Drug: AZD7762
- Drug: Irinotecan
Primary outcomes (1)
- measure
- The primary objective of this study is to assess the safety and tolerability of AZD7762 alone and in combination with Irinotecan
- timeFrame
- assessed after each course of treatment
Secondary outcomes (1)
- measure
- To determine the single-dose (after the first single-agent dose) and combination-dose (afer the 2nd combination dose) pharmacokinetics (PK) of AZD7762.
- timeFrame
- assessed after each course of treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Advanced solid tumors for which standard treatment doesn't exist or is no longer effective. * Must be suitable for treatment with irinotecan * Relatively good overall health other than your cancer Exclusion Criteria: * Poor bone marrow function (not producing enough blood cells) * Serious heart conditions * Poor liver or kidney function * Any prior anthracycline treatment
References
Publications (0)
Data not yet available